Edbio and Lilly Pharmaceutical Co., Ltd. have reached a target drug clinical research cooperation
-
Last Update: 2019-06-25
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Yesterday, Xiamen Biomedical Technology Co., Ltd announced that it will cooperate with Loxo oncology, Inc (a subsidiary of Lilly pharmaceutical) in the clinical research of targeted drugs, and will become a diagnostic agent accompanying the clinical trials of loxo-292 in mainland China, Taiwan and Japan The specific content is as follows: This article is reprinted by yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
